A Rare Case of Double-antibody-positive Renal Vasculitis: Are we in a Hurry to Start Tuberculosis Medicines?

Author:

Kumar Sunil1,Kumari Ankita1,Mistry Jimit N.1,Naredi Mohit1,Chander Ayushi1

Affiliation:

1. Department of Respiratory Medicine, Pacific Medical College and Hospital, Udaipur, Rajasthan, India

Abstract

Double antibody positive renal vasculitis (anti GBM antibody and pANCA) is a rare form of small vessel vasculitis associated with poor outcome. It is difficult to decide which antibody is the precursor in these cases. We report here such a rare case of double antibody positive renal vasculitis which was started on anti tubercular medicine for a positive mantoux test and interferon gamma release assay. The possible reasons for these antibodies in this may be a complication of COVID-19 infection or vaccine, adverse drug effect of antitubercular medicines or a paradoxical reaction during the tuberculosis treatment. The patient could not survive beyond two months of diagnosis because of rapidly declining renal functions. This case highlights the importance of a meticulous clinical approach, supports two week tuberculosis medicines trial and an early and careful dealing of non responders during tuberculosis treatment especially in patients whose diagnosis is not microbiologically confirmed.

Publisher

Medknow

Reference19 articles.

1. Goodpasture’s syndrome: A clinical update;Greco;Autoimmun Rev,2015

2. A rare case of double antibody-positive rapidly progressive glomerulonephritis: A therapeutic challenge;Bell;J Investig Med High Impact Case Rep,2021

3. Cutting edge issues in Goodpasture’s disease;Chan;Clin Rev Allergy Immunol,2011

4. Clinical features and outcome of patients with both ANCA and anti-GBM antibodies;Levy;Kidney Int,2004

5. ANCA-associated vasculitis flare might be provoked by COVID-19 infection: A case report and a review of the literature;Ozcan;Clin Kidney J,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3